Company and Product Background
Nuvaira, Inc. is a privately held medical device company that develops minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. Specifically, the company has developed a novel, catheter-based system to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves in a procedure called Targeted Lung Denervation (TLD). Nuvaira received CE Mark approval for its Nuvaira™ Lung Denervation System in January 2016.
Targeted Lung Denervation is a simple, one-time bronchoscopic procedure that disrupts overactive nerves in the lungs, thereby opening up the airways to improve breathing. Similar to anticholinergic drugs (a class of drugs that block the action of the neurotransmitter acetylcholine in the lungs), TLD targets the parasympathetic innervation of the lungs and has the potential to provide a lasting improvement in lung function, exercise capacity and quality of life for patients with obstructive lung disease.
Nuvaira’s proprietary technology and accompanying procedure have been used in the recently completed AIRFLOW-2 randomized, sham-controlled COPD clinical trial (RCT) in Europe and the ongoing RELIEF-1 asthma trial. Nuvaira is headquartered in Minneapolis, Minnesota and has more than 70 patents issued and pending worldwide.